These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36858453)

  • 1. US public investment in development of mRNA covid-19 vaccines: retrospective cohort study.
    Lalani HS; Nagar S; Sarpatwari A; Barenie RE; Avorn J; Rome BN; Kesselheim AS
    BMJ; 2023 Mar; 380():e073747. PubMed ID: 36858453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic.
    Eren Vural I; Herder M; Doll A; Graham JE
    Int J Health Policy Manag; 2023; 12():6936. PubMed ID: 37579382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the 100 days mission for vaccines on COVID-19: a mathematical modelling study.
    Barnsley G; Olivera Mesa D; Hogan AB; Winskill P; Torkelson AA; Walker DG; Ghani AC; Watson OJ
    Lancet Glob Health; 2024 Nov; 12(11):e1764-e1774. PubMed ID: 39424569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models.
    Alonso Ruiz A; Bezruki A; Shinabargar E; Large K; Vieira M; Slovenski I; Liu Y; Agarwal S; Becker A; Moon S
    Global Health; 2024 Mar; 20(1):25. PubMed ID: 38532484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA vaccines for COVID-19 and diverse diseases.
    Hussain A; Yang H; Zhang M; Liu Q; Alotaibi G; Irfan M; He H; Chang J; Liang XJ; Weng Y; Huang Y
    J Control Release; 2022 May; 345():314-333. PubMed ID: 35331783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19.
    Yu H
    Inquiry; 2021; 58():469580211059734. PubMed ID: 34855535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving pandemic preparedness through better, faster influenza vaccines.
    Newland M; Durham D; Asher J; Treanor JJ; Seals J; Donis RO; Johnson RA
    Expert Rev Vaccines; 2021 Mar; 20(3):235-242. PubMed ID: 33576708
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries.
    Peacocke EF; Heupink LF; Frønsdal K; Dahl EH; Chola L
    BMJ Open; 2021 Sep; 11(9):e049505. PubMed ID: 34593496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Sarpatwari A
    J Law Med Ethics; 2023; 51(S2):28-34. PubMed ID: 38433672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19.
    Iqbal SM; Rosen AM; Edwards D; Bolio A; Larson HJ; Servin M; Rudowitz M; Carfi A; Ceddia F
    Front Public Health; 2024; 12():1429265. PubMed ID: 39175908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Funding Sources of Therapeutic and Vaccine Clinical Trials for COVID-19 vs Non-COVID-19 Indications, 2020-2021.
    Angelis A; Suarez Alonso C; Kyriopoulos I; Mossialos E
    JAMA Netw Open; 2022 Aug; 5(8):e2226892. PubMed ID: 35972740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Return on investment: a fuller assessment of the benefits and cost savings of the US publicly funded family planning program.
    Frost JJ; Sonfield A; Zolna MR; Finer LB
    Milbank Q; 2014 Dec; 92(4):696-749. PubMed ID: 25314928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NIH funding for vaccine readiness before the COVID-19 pandemic.
    Kiszewski AE; Cleary EG; Jackson MJ; Ledley FD
    Vaccine; 2021 Apr; 39(17):2458-2466. PubMed ID: 33781600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meeting Summary: Global Vaccine and Immunization Research Forum, 2021.
    Ford A; Hwang A; Mo AX; Baqar S; Touchette N; Deal C; King D; Earle K; Giersing B; Dull P; Hall BF
    Vaccine; 2023 Mar; 41(11):1799-1807. PubMed ID: 36803897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.